Steve Perrin, Ph.D., will present at the IXA Congress on immunosuppression and the anti-CD154 pathway in Geneva.
Quiver AI Summary
Eledon Pharmaceuticals, Inc. announced that its President and Chief Scientific Officer, Dr. Steve Perrin, will participate in a plenary session at the 18th Congress of the International Xenotransplantation Association in Geneva from September 30 to October 3, 2025. Dr. Perrin's lecture, titled "Anti-CD154 Pathway Blockade," will take place on October 1, 2025, from 10:30 a.m. to 12:00 p.m. CET. Eledon is a biotechnology company focused on developing immune-modulating therapies, including its lead product, tegoprubart, an anti-CD40L antibody that targets CD40 Ligand, which plays a significant role in immune system activation. Eledon conducts studies related to kidney transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS) and is based in Irvine, California.
Potential Positives
- Eledon Pharmaceuticals is gaining visibility and recognition in the scientific community by having its President and Chief Scientific Officer, Steve Perrin, participate in a prestigious plenary session at the 18th Congress of the International Xenotransplantation Association.
- The focus on the anti-CD154 (CD40L) pathway in the lecture indicates Eledon's commitment to advancing research in immune-modulating therapies, potentially enhancing their reputation as a leader in the field.
- The participation in an international congress can foster valuable networking opportunities and collaborations that may benefit Eledon's research and development efforts.
- The emphasis on tegoprubart as an investigational product for serious conditions showcases the company's innovation and dedication to addressing unmet medical needs, which could attract investor interest.
Potential Negatives
- Company's lead investigational product, tegoprubart, is still in the clinical stage, indicating it has not yet achieved market entry or commercialization, which may raise concerns about its viability and the company's financial outlook.
- Participation in a session titled "Immunosuppression, Immune Monitoring, Anti-CD154 Pathway Blockade: How Far do We Need to Go?" may highlight uncertainties or ongoing debate in the medical community regarding the effectiveness of the CD40L target, potentially signaling risks to investor confidence.
- Company's focus on complex therapeutic areas like xenotransplantation and ALS may be seen as high-risk due to the challenges associated with these conditions, which could impact investor sentiment negatively.
FAQ
What is Eledon Pharmaceuticals' recent announcement?
Eledon Pharmaceuticals announced that Dr. Steve Perrin will present at the 18th Congress of the International Xenotransplantation Association.
When is the plenary session featuring Dr. Perrin?
The plenary session is scheduled for Wednesday, October 1, 2025, from 10:30 a.m. to 12:00 p.m. CET.
What is the focus of Dr. Perrin's presentation?
Dr. Perrin's presentation will focus on immunosuppression and the anti-CD154 pathway blockade in xenotransplantation.
What is tegoprubart?
Tegoprubart is Eledon's investigational anti-CD40L antibody targeting the CD40 Ligand for immune-modulating therapy.
Where is Eledon Pharmaceuticals located?
Eledon Pharmaceuticals is headquartered in Irvine, California.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ELDN Hedge Fund Activity
We have seen 49 institutional investors add shares of $ELDN stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,601,531 shares (+398.6%) to their portfolio in Q2 2025, for an estimated $7,050,149
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 1,176,735 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,989,131
- POINT72 ASSET MANAGEMENT, L.P. removed 1,095,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,712,050
- GEODE CAPITAL MANAGEMENT, LLC added 717,223 shares (+107.6%) to their portfolio in Q2 2025, for an estimated $1,943,674
- MILLENNIUM MANAGEMENT LLC removed 639,207 shares (-78.8%) from their portfolio in Q2 2025, for an estimated $1,732,250
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 566,729 shares (-35.7%) from their portfolio in Q2 2025, for an estimated $1,535,835
- BLUE OWL CAPITAL HOLDINGS LP removed 490,000 shares (-26.9%) from their portfolio in Q2 2025, for an estimated $1,327,900
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ELDN Analyst Ratings
Wall Street analysts have issued reports on $ELDN in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/02/2025
- Craig-Hallum issued a "Buy" rating on 07/25/2025
To track analyst ratings and price targets for $ELDN, check out Quiver Quantitative's $ELDN forecast page.
$ELDN Price Targets
Multiple analysts have issued price targets for $ELDN recently. We have seen 2 analysts offer price targets for $ELDN in the last 6 months, with a median target of $10.5.
Here are some recent targets:
- Yi Chen from HC Wainwright & Co. set a target price of $9.0 on 09/02/2025
- An analyst from Craig-Hallum set a target price of $12.0 on 07/25/2025
Full Release
IRVINE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will participate in a plenary session at the upcoming 18 th Congress of the International Xenotransplantation Association (IXA) taking place from September 30–October 3, 2025, in Geneva, Switzerland.
Details are as follows:
Plenary Session:
Immunosuppression, Immune Monitoring, Anti-CD154* Pathway Blockade: How Far do We Need to Go?
Lecture Title:
201.2 Anti-CD154 Pathway Blockade
Date:
Wednesday, October 1, 2025
Time:
10:30 a.m. – 12:00 p.m. CET
*CD154 is also known as CD40L or CD40 Ligand
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com .
Follow Eledon Pharmaceuticals on social media: LinkedIn ; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
[email protected]
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
[email protected]
Source: Eledon Pharmaceuticals
